Good news comes in succession! Shanghai Biotecan Clinical Laboratory successfully passed the verification of detection capability for SARS-CoV-2, helping Biotecan become one of the firstly certified Independent Clinical Laboratories for new crown virus detection in China.

To coordinate the prevention of COVID-19 and ensure the quality of nucleic acid testing, Shanghai Clinical Laboratory Center provides capability verification service for novel coronavirus nucleic acid detection for laboratories meeting biosafety standards and qualified with gene amplification tests.

As one of the national high-tech enterprises and a leading molecular diagnosis company in China, Shanghai Biotecan Clinical Laboratory has successively undertaken and participated in more than 20 national and regional key research projects. In term of virus detection, Biotecan owns five cutting-edge technology platforms including point-of-care testing, quantitative real-time PCR, droplet digital PCR, isothermal amplified microfluidic detection and metagenomic next-generation sequencing, which can offer system solutions for rapid screening, diagnosis and monitoring of virus.